References
- Harris JM, Chess RB. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2003:2:215-21
- NEKTAR Therapeutics Co. Polyethylene glycol and derivatives for advanced PEGylation. Catalogue 2005-2006 Nektar Advanced PEGylation
- Veronese FM, Harris JM. Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 2002:54:453-6 https://doi.org/10.1016/S0169-409X(02)00020-0
- Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE et al. Rational Design of a Potent, Long-Lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol- Conjugated Interferon-2a for the Treatment of Hepatitis C. Bioconjug Chem 2001:12:195-202 https://doi.org/10.1021/bc000082g
- Ng EW, Shima DT, Calias P, Cunningham Jr. ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006:5:123-32 https://doi.org/10.1038/nrd1955
- Cheng TL, Wu PY, Wu MF, Chern JW, Roffler SR. Accelerated clearance of polyethylene glycol-modified proteins by antipolyethylene glycol IgM. Bioconjug Chem 1999:10:520-8 https://doi.org/10.1021/bc980143z
- Dams ETM, Laverman P, Oyen WJG, Storm G, Scherphof GL, van Der Meer JW et al. Accelerated Blood Clearance and Altered Biodistribution of Repeated Injections of Sterically Stabilized Liposomes. J Pharmacol Exp Ther 2000:292:1071-9
- Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003:55:1261-77 https://doi.org/10.1016/S0169-409X(03)00108-X
- Mahesh C. Polylactides/Glycolides-Excipients for Injectable Drug. Drug Del Tech 2002:2:21
- Johnson OL, Cleland JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W et al. A month−long effect from a single injection of microencapsulated human growth hormone. Nat Med 1996:2:795-9 https://doi.org/10.1038/nm0796-795
- Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Targeting 2008:16:108-23 https://doi.org/10.1080/10611860701794353
- Shenoy DB, Amiji MM. Poly(ethylene oxide)-modified poly (epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 2005:293:261-70 https://doi.org/10.1016/j.ijpharm.2004.12.010
- Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 2007:121:1830-80
- Vercruysse KP, Prestwich GD. Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst 1998:15:513-55
- Motokawa K, Hahn SK, Nakamura T, Miyamoto H, Shimoboji T. Selectively crosslinked hyaluronic acid hydrogels for. sustained release formulation of erythropoietin. J Biomed Mat Res 2006:78A:459-65 https://doi.org/10.1002/jbm.a.30759
- Oh EJ, Kang SW, Kim BS, Jiang G, Cho IH, Hahn SK. Control of the molecular degradation of hyaluronic acid hydrogels for tissue augmentation. J Biomed Mater Res A 2008:86:685-93
- Luo Y, Prestwich GD. Synthesis and Selective Cytotoxicity of a Hyaluronic Acid-Antitumor Bioconjugate. Bioconj Chem 1999: 10:755-63 https://doi.org/10.1021/bc9900338
- Pusateri, AE., McCarthy SJ, Gregory KW, Harris RA, Cardenas L, McManus LT et al. Effect of a chitosan-based hemostatic dressing on blood loss and survival in a model of severe venous hemorrhage and hepatic injury in swine. Journal of Trauma 2003:4:177-82
- Kean T, Roth S, Thanou M. Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J Control Release 2003:103:643-653 https://doi.org/10.1016/j.jconrel.2005.01.001
- Dodane V, Vivivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Technol Today 1998:1:246-253 https://doi.org/10.1016/S1461-5347(98)00059-5
- Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res 1998:15:1326-31 https://doi.org/10.1023/A:1011929016601
- Xu Y, Du Y. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 2003:250:215-26 https://doi.org/10.1016/S0378-5173(02)00548-3
- Qi LF, Xu ZR, Li Y, Jiang X, Han XY. In vitro effects of chitosan nanoparticles on proliferation of human gastric carcinoma cell line MGC803 cells. World J Gastroenterol 2005:11:5136-41
- Qi L, Xu Z, Chen M. In vitro and in vivo suppression of hepatocellular carcinoma growth by chitosan nanoparticles. Eur J Cancer 2007:43:184-93 https://doi.org/10.1016/j.ejca.2006.08.029
- Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006:5:1909-17 https://doi.org/10.1158/1535-7163.MCT-06-0141
- Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A et al. Goldberg RM, Lindley C, Claire Dees E..Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (abraxane(R)) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007:60:759-66 https://doi.org/10.1007/s00280-007-0423-x
- Brahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002:8:1038-44
- Dreis S, Rothweiler F, Michaelis M, Cinatl J Jr, Kreuter J, Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int J Pharm 2007:341:207-14 https://doi.org/10.1016/j.ijpharm.2007.03.036
- Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997:54:15-21
- Hussein MA, Wood L, Hsi E, et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002:95:2160-8 https://doi.org/10.1002/cncr.10946
- Rifkin RM, Gregory SA, Mohrbacher A. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer 2006: 106:848-58 https://doi.org/10.1002/cncr.21662
- Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002:95: 2160-8 https://doi.org/10.1002/cncr.10946
- Vlugt-Wensink KD, Jiang X, Schotman G, Kruijtzer G, Vredenberg A, Chung JT et al. In vitro degradation behavior of microspheres base don cross-linked dextran. Biomacromol 2006: 7:2983-90 https://doi.org/10.1021/bm060385z
- Allen TM, Cullis PR. Drug Delivery Systems: Entering the Mainstream. Science 2004:303:1818-22 https://doi.org/10.1126/science.1095833
- Prescott JH, Lipka S, Samuel Baldwin, Sheppard Jr NF, Maloney JM, Coppeta J et al. Chronic, programmed polypeptide delivery from an implanted, multireservoir microchip device. Nat Biotechnol 2006:24:437-8 https://doi.org/10.1038/nbt1199
- Duros Technology Platform. http://www.durect.com/pdf/duros_ fact_sheet2001.pdf. Accessed Oct. 2008
- Staples M, Daniel K, Cima MJ, Langer R. Pharmaceutical Research 2006:23:847-863 https://doi.org/10.1007/s11095-006-9906-4
- Brent G. http://www.hpl.hp.com/news/2008/jan-mar/skin_patch. html. Accessed Oct. 2008
- Kwon SY. In Vitro Evaluation of Transdermal Drug Delivery by a Micro-needle Patch. Controlled Release Society 31st Annual Meeting, TRANSACTIONS 2004, Abstract #115
- Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discovery 2008:7:771-82 https://doi.org/10.1038/nrd2614
- Allen TM, Cullis PR. Drug Delivery Systems: Entering the Mainstream. Science 2004:303:1818-22 https://doi.org/10.1126/science.1095833
- Hashida M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm Res 1998:15:128-32 https://doi.org/10.1023/A:1011921324952
- Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. Journal of Drug Targeting 2008:16:108-23 https://doi.org/10.1080/10611860701794353
- Banks WA, Kastin AJ. Characterization of lectin-mediated brain uptake of HIV-1 GP120. J Neurosci Res 1998:54:522-9 https://doi.org/10.1002/(SICI)1097-4547(19981115)54:4<522::AID-JNR9>3.0.CO;2-O
- Fischer D, Kissel T. Histochemical characterization of primary capillary endothelial cells from porcine brains using monoclonal antibodies and fluorescein isothiocyanate-labelled lectins: Implications for drug delivery. Eur J Pharm Biopharm 2001:52:1-11 https://doi.org/10.1016/S0939-6411(01)00159-X
- Mo Y, Lim LY. Preparation and in vitro anticancer activity of WGA-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Release 2005:107:30-42 https://doi.org/10.1016/j.jconrel.2004.06.024
- Jeong YI, Seo SJ, Park IK, Lee HC, Kang IC, Akaike T et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(gamma-benzyl L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm 2005:296:151-61 https://doi.org/10.1016/j.ijpharm.2005.02.027
- Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005:4:363-74 https://doi.org/10.1177/153303460500400405
- Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006:121:159-76 https://doi.org/10.1016/j.clim.2006.06.006
- Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006:121:144-58 https://doi.org/10.1016/j.clim.2006.06.010
- Xu Z, Gu W, Huang J, Sui H, Zhou Z, Yang Y et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 2005:288:361-8 https://doi.org/10.1016/j.ijpharm.2004.10.009
- Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 2002:54:675- 93 https://doi.org/10.1016/S0169-409X(02)00042-X
- Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005:4:363-74 https://doi.org/10.1177/153303460500400405
- Zhang Z, Huey LS, Feng SS. Folate-decorated poly(lactidecoglycolide)- vitamin E TPGS NPs for targeted drug delivery. Biomaterials 2007:28:1889-99 https://doi.org/10.1016/j.biomaterials.2006.12.018
- Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004:10:415-27 https://doi.org/10.1158/1078-0432.CCR-0642-03
- Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother 2006:29:1-9 https://doi.org/10.1097/01.cji.0000192105.24583.83
- Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006:66: 6732-40 https://doi.org/10.1158/0008-5472.CAN-05-4199
- Burgstaller P, Jenne A, Blind M. 2002. Aptamers and aptazymes: Accelerating small molecule drug discovery. Curr Opin Drug Discov Devel 5:690-700
- Pestourie C, Tavitian B, Duconge F. 2005. Aptamers against extracellular targets for in vivo applications. Biochimie 87:921- 30 https://doi.org/10.1016/j.biochi.2005.04.013
- Hicke BJ, Stephens AW. Escort aptamers: A delivery service for diagnosis and therapy. J Clin Invest 2000:106:923-8 https://doi.org/10.1172/JCI11324
- Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 2006:3:311-24 https://doi.org/10.1517/17425247.3.3.311
- Moghimi SM, Hunter AC, Murray JC. Long- circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001:53:283-318
- Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003:8:1112-20 https://doi.org/10.1016/S1359-6446(03)02903-9
- Cai W, Chen X. Nanoplatforms for targeted molecular imaging in living subjects. Small. 2007:3:1840-54 https://doi.org/10.1002/smll.200700351
- Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008:49 Suppl 2:113S-28S https://doi.org/10.2967/jnumed.107.045922
- Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissues. Adv Drug Deliv Rev 2004:55:329-47 https://doi.org/10.1016/S0169-409X(02)00228-4
- Oh KT, Bronich TK, Kabanov AV. Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic block copolymers. J Control Release 2004:94:411-22 https://doi.org/10.1016/j.jconrel.2003.10.018
- Lukyanov AN, Gao ZG, Torchilin VP. Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release 2003:91:97-102 https://doi.org/10.1016/S0168-3659(03)00217-7
- Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004:303:1818-1822 https://doi.org/10.1126/science.1095833
- Moghimi SM, Hunter AC, Murray JC. Long- circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001:53:283-31
- Biancco, A. Carbon nanotubes for the delivery of therapeutic molecules. Exp. Opin. Drug Deliv 2004:1:57-65 https://doi.org/10.1517/17425247.1.1.57
- Lopez CF, Nielsen SO, Moore PB, Klein ML. Understanding nature's design for a nanosyringe. Proc Natl Acad Sci USA 2004:101:4431-4
- Ali SS, Hardt JI, Quick KL, Kim-Han JS, Erlanger BF, Huang TT et al. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radical Biol Med 2004:37:1191-202 https://doi.org/10.1016/j.freeradbiomed.2004.07.002
- Park KH, Chhowalla M, Iqbal Z, Sesti F. Single-walled carbon nanotubes are a new class of ion channel blockers. J Biol Chem 2003:278:50212-6 https://doi.org/10.1074/jbc.M310216200
- Tomalia DA, Frechet JMJ. Discovery of dendrimers and dendritic polymers: a brief historical perspective. J Polym SciPart A: Polym Chem 2002:40:2719-28 https://doi.org/10.1002/pola.10301
- Haag R. Supramolecular drug-delivery systems based on polymeric core-shell architectures. Angew Chem Int Ed Engl 2004:43:278-82 https://doi.org/10.1002/anie.200301694
- Rosa BA, Schengrund CL. Dendrimers and antivirals: a review. Curr Drug Targets Infect Disord 2005:5:247-54 https://doi.org/10.2174/1568005054880127
- Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN. Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 2007:18:1391-6 https://doi.org/10.1021/bc060367e
- Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007:7: 3065-70 https://doi.org/10.1021/nl071546n
- Hoshino A, Fujioka K, Oku T, Nakamura S, Suga M, Yamaguchi Y, et al. Quantum dots targeted to the assigned organelle in living cells. Microbiol Immunol 2004:48:985-94 https://doi.org/10.1111/j.1348-0421.2004.tb03621.x
- Howarth M, Takao K, Hayashi Y, Ting AY. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc Natl Acad Sci USA 2005:102:7583-8
- Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004:22:969-76 https://doi.org/10.1038/nbt994
- Derfus AM, Chan WCW, Bhatia SN. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett 2004:4:11-8 https://doi.org/10.1021/nl0347334
- Cho SJ, Maysinger D, Jain M, Roder B, Hackbarth S, Winnik FM. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir 2007:23:1974-80 https://doi.org/10.1021/la060093j
- Green M, Howman E. Semiconductor quantum dots and free radical induced DNA nicking. Chem Commun (Camb) 2005: 121-3
- Choi AO, Cho SJ, Desbarats J, Lovric J, Maysinger D. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnol 2007:5:1-5 https://doi.org/10.1186/1477-3155-5-1
- Lovric J, Cho SJ, Winnik FM, Maysinger D. Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death. Chem Biol 2005:12:1227-34 https://doi.org/10.1016/j.chembiol.2005.09.008
- Zhu MQ, Han JJ, Li AD. CdSe/CdS/SiO2 core/shell/shell nanoparticles. J Nanosci Nanotechnol 2007:7:2343-8 https://doi.org/10.1166/jnn.2007.438
- Kim D, Park S, Lee JH, Jeong YY, Jon S. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo X-ray computed tomography imaging. J Am Chem Soc 2007: 129:7661-5 https://doi.org/10.1021/ja071471p
- Edwards EW, Chanana M, Wabg DY, Mohwald H. Stimuliresponsive transport of nanoparticles across water-oil interfaces. Angew Chem Int Ed Engl 2008:47:320-3 https://doi.org/10.1002/anie.200702597
- Esenturk EN, Walker AR Surface-enhanced Raman scattering spectroscopy via gold nanostars. J Raman Spectroscopy 2008: Sep:Epub ahead of print
- Schellenberger EA, Reynolds F, Weissleder R, Josephson L. Surface-functionalized nanoparticle library yields probes for apoptotic cells. Chem Bio Chem 2004:5:275-9 https://doi.org/10.1002/cbic.200300713
- Jaffer FA, Weissleder R. Seeing within—molecular imaging of the cardiovascular system. Circ Res 2004:94:433-45 https://doi.org/10.1161/01.RES.0000119321.18573.5A
- Perez, JM, Josephson L, Weissleder R. Use of magnetic nanoparticles as nanosensors to probe for molecular interactions. Chem Bio Chem 2004:5:261-4 https://doi.org/10.1002/cbic.200300730
- Gilad AA, Walczak P, McMahon MT, Na HB, Lee JH, An K et al. MR Tracking of Transplanted Cells With 'Positive Contrast' Using Manganese Oxide Nanoparticles. Magnetic Resonance in Medicine 2008:60:1-7 https://doi.org/10.1002/mrm.21622
- Cheon J, Lee JH. Synergistically Integrated Nanoparticles as Multimodal Probes for Nanobiotechnology. Acc Chem Res 2008 Aug:Epub ahead of print